APOL6

APOL6 Full Name

apolipoprotein L 6

APOL6 Introduction

APOL6 (apolipoprotein L6) is a member of the apolipoprotein L (APOL) gene family, which comprises six genes (APOL1-APOL6) located in a cluster on human chromosome 22q12.3. The APOL family proteins are characterized by a conserved C-terminal pore-forming domain and an N-terminal signal peptide that targets them to the secretory pathway. APOL6 encodes a 337-amino acid protein with a molecular weight of approximately 38 kDa that is primarily localized to the endoplasmic reticulum and the cytosol. Unlike APOL1, which is secreted and functions in high-density lipoprotein metabolism and trypanosome lysis, APOL6 is an intracellular protein that plays critical roles in innate immunity, antiviral defense, and the regulation of apoptosis. APOL6 expression is strongly induced by interferons (IFNs), particularly type I IFNs (IFN-alpha and IFN-beta) and type II IFN (IFN-gamma), positioning it as an interferon-stimulated gene (ISG) with broad-spectrum antiviral and antibacterial activities. APOL6 inhibits the replication of diverse viruses including hepatitis C virus (HCV), vesicular stomatitis virus (VSV), encephalomyocarditis virus (EMCV), dengue virus (DENV), and human immunodeficiency virus (HIV), primarily by inducing apoptosis of infected cells and by disrupting intracellular membrane trafficking.

Figure 1. Schematic structure of APOL6.

Gene Structure and Protein Architecture
The human APOL6 gene spans approximately 3.5 kb and contains 7 exons. The full-length protein consists of 337 amino acids and contains several functionally important domains characteristic of the APOL family. The N-terminal region contains a signal peptide (amino acids 1-29) that targets the protein to the endoplasmic reticulum, followed by a membrane-addressing domain that is necessary and sufficient for Golgi localization. The central region contains a leucine zipper-like motif that may mediate protein-protein interactions and oligomerization. The C-terminal region contains the highly conserved pore-forming domain that is shared among all APOL family members. This domain adopts a helix-turn-helix conformation that inserts into lipid bilayers, creating ion channels that disrupt membrane integrity. APOL6 also contains a putative BH3 (Bcl-2 homology 3) domain that mediates its interaction with anti-apoptotic Bcl-2 family proteins and contributes to its pro-apoptotic activity. Unlike APOL1, which has undergone positive selection in African populations and confers resistance to Trypanosoma brucei, APOL6 does not contain the SRA (serum resistance-associated) domain and is not secreted into the bloodstream. The protein is localized primarily to the cytosol and associates with intracellular membranes, including the endoplasmic reticulum and Golgi apparatus.

Clinical Significance: Hepatitis C, Cancer, and Inflammatory Diseases
APOL6 has been implicated in the pathogenesis and treatment response of several human diseases, particularly hepatitis C virus (HCV) infection, cancer, and inflammatory conditions. In HCV infection, APOL6 expression is induced by interferon-based therapy, and high APOL6 expression correlates with sustained virological response (SVR) to pegylated interferon-alpha and ribavirin treatment. Patients who achieve viral clearance have significantly higher baseline and on-treatment APOL6 expression levels compared to non-responders, suggesting that APOL6 could serve as a predictive biomarker for interferon responsiveness. Genetic variants in the APOL6 gene, particularly the single nucleotide polymorphism rs2072932 (located in the 3' untranslated region), have been associated with altered APOL6 expression and with spontaneous clearance of HCV infection, though these findings require replication in larger cohorts. In cancer, APOL6 functions as a tumor suppressor in certain contexts. APOL6 expression is frequently downregulated in breast cancer, lung cancer, gastric cancer, and colorectal cancer compared to adjacent normal tissues, and low APOL6 expression correlates with advanced tumor stage, lymph node metastasis, and poor patient survival. Interferon-induced APOL6 expression suppresses cancer cell proliferation by inducing apoptosis and by inhibiting the epithelial-mesenchymal transition (EMT). Conversely, in some cancer types, APOL6 expression may be upregulated and contribute to chemoresistance, reflecting the context-dependent roles of the APOL family. In inflammatory diseases, APOL6 has been studied in systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), where dysregulated interferon signaling and APOL6 expression contribute to disease pathogenesis. APOL6 expression is elevated in the peripheral blood mononuclear cells of SLE patients and correlates with disease activity scores and interferon signature. However, the functional role of APOL6 in these conditions remains to be fully elucidated. In preeclampsia, a pregnancy disorder characterized by hypertension and proteinuria, APOL6 expression is increased in placental tissue and may contribute to the inflammatory and apoptotic processes that underlie placental dysfunction.

Alternate Names for APOL6

APOL6; apolipoprotein L 6; apolipoprotein L6; 2310076O14Rik; Apol6